Circulating tumor DNA for minimal residual disease in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant: a multi-center prospective study.
Not Applicable
Recruiting
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Registration Number
- JPRN-UMIN000033003
- Lead Sponsor
- Kanto Study Group for Cell Therapy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1.Any patient who decline to register 2.Any patient who are considered as inappropriate to register by attending physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate 1-year cumulative incidence of relapse rate according to circulating tumor DNA status post allogeneic hematopoietic stem cell transplant
- Secondary Outcome Measures
Name Time Method 1. To evaluate 1-year overall survival rate according to circulating tumor DNA status post allogeneic hematopoietic stem cell transplant 2. To compare the utility of circulating tumor DNA status and conventional biomarkers 3. To compare the profiles of the somatic mutation, gene expression, and immunological cell status between diagnostic and relapsed samples from bone marrow or peripheral blood